Form 4: Tandem Diabetes Care EVP & Chief Legal Officer Receives Significant Equity Awards

Shannon Marie Hansen, Executive Vice President and Chief Legal Officer of Tandem Diabetes Care Inc., reported the acquisition of 23,000 Performance Stock Units and 23,002 Restricted Stock Units on May 30, 2025, under the company's long-term incentive plan.

Summary

• Shannon Marie Hansen, EVP & Chief Legal Officer of Tandem Diabetes Care Inc. (TNDM), reported changes in her beneficial ownership of company securities.
• On May 30, 2025, Ms. Hansen acquired 23,000 Performance Stock Units (PSUs) and 23,002 Restricted Stock Units (RSUs).
• These awards were granted pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended.
• Each PSU represents a contingent right to receive one share of common stock, with the number of shares issued potentially ranging from 0% to 200% based on company performance metrics as of December 31, 2027, and continued service.
• Each RSU represents a contingent right to receive one share of common stock or cash in lieu thereof.
• RSUs will vest as to 33% of the total on May 15, 2026, with the remaining shares vesting in eight equal quarterly installments thereafter.
• Following these transactions, Ms. Hansen directly owns 16,742 shares of Common Stock and indirectly owns 1,935 shares through the Shannon M. Hansen Trust.
• Additionally, Ms. Hansen beneficially owns 23,000 PSUs and 23,002 RSUs directly.

Sentiment

Score: 7

Explanation: The filing indicates a significant equity award to a key executive, aligning their interests with long-term company performance. This is generally viewed positively for corporate governance and executive retention, although it does not directly impact immediate financial performance or share price.

Positives

• The granting of Performance Stock Units (PSUs) and Restricted Stock Units (RSUs) to a key executive aligns management's interests with long-term shareholder value creation.
• The performance-based nature of the PSUs incentivizes the executive to achieve specific company metrics, potentially driving stronger financial results.
• The long-term vesting schedules for both PSUs and RSUs promote executive retention and commitment to the company's sustained success.

Risks

• The Performance Stock Units (PSUs) are subject to the achievement of pre-defined performance metrics by December 31, 2027; if minimum performance is not met, no PSUs will vest, posing a risk to the executive's compensation and potentially indicating underperformance.
• The number of shares issued from PSUs can range from 0% to 200%, introducing variability based on future company performance.

Future Outlook

The future outlook for the executive's compensation is tied to the company's performance through December 31, 2027, for PSUs, and continued service with a vesting schedule extending beyond May 2026 for RSUs. This indicates a long-term commitment and incentive structure for the EVP & Chief Legal Officer.

Industry Context

Executive equity awards, particularly those tied to performance and long-term vesting, are a standard practice in the medical device and biotechnology industries. They are designed to attract, retain, and motivate key talent by aligning their financial interests with the company's long-term strategic goals and shareholder returns. This filing reflects a typical compensation structure for a senior executive in a publicly traded company like Tandem Diabetes Care.

Corporate Governance

Related Party Transactions

• Shannon M. Hansen indirectly holds 1,935 shares of Common Stock through the Shannon M. Hansen Trust dated July 8, 2003, of which she is the Trustee. This is a common arrangement for personal asset management.

Stakeholder Impact

• Shareholders: The equity awards align the interests of a key executive with long-term shareholder value, potentially leading to improved company performance and governance.
• Employees: The compensation structure for senior leadership can set a precedent or reflect the company's overall approach to long-term incentives.

Next Steps

• Continued service of Shannon Marie Hansen through the PSU measurement date of December 31, 2027, and RSU vesting periods.
• Achievement of pre-defined performance metrics for PSUs by December 31, 2027.
• Vesting of RSUs, with the first tranche on May 15, 2026, followed by eight equal quarterly installments.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Transaction, Equity Award, Performance Stock Unit, Restricted Stock Unit, Executive Compensation, Shannon Marie Hansen, Long-Term Incentive Plan, Corporate Governance, Diabetes Management